Study of the Thor Laser Atherectomy System to Treat Blockages in Leg Arteries Caused by Peripheral Artery Disease in Adults
Led by Philips Clinical & Medical Affairs Global · Updated on 2026-06-11
155
Participants Needed
29
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the Thor system in adults aged 18 years and older who have new, untreated calcified blockages in leg arteries caused by peripheral artery disease PAD. The study aims to determine whether the Thor system is safe and effective for treating these lesions. Patients experience leg pain due to poor blood flow, and the study will observe how the Thor system works in this setting.
All participants will receive treatment using the Thor laser atherectomy system, which targets calcified lesions to improve blood flow. During the procedure, doctors may also use additional devices such as angioplasty balloons, drug-coated balloons, stents, and clot-collecting filters if needed. The procedure includes x-ray imaging, and patients will be monitored closely until discharge or for up to 24 hours after treatment.
Participants will have follow-up visits at discharge, 30 days, 6 months, and 12 months after the procedure. These visits include medical history reviews, physical exams of the legs, blood flow tests using arm and leg blood pressure comparisons, ultrasound imaging, and questionnaires about walking ability and quality of life. The study will measure outcomes such as freedom from major adverse events, procedural success, lesion openness, and improvements in walking and health surveys over one year.
CONDITIONS
Brief Title
The THOR IDE Study
Research Team
D
Danielle Op den Kamp
A
Amanda Franey
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Thor Laser Atherectomy
Current Guideline Endovascular Therapy
What is it?
Laser-powered endovascular device for modifying calcified lesions and reopening blocked femoropopliteal or popliteal arteries.
Balloon angioplasty—with or without conventional atherectomy—used to treat calcified, obstructed femoropopliteal and popliteal arteries as recommended by current guidelines.
Primary use
Used to ablate and modify moderate-to-severe calcified peripheral artery lesions to restore blood flow in eligible PAD patients.
Used to re-expand narrowed peripheral arteries, and optionally debulk calcified plaque, to improve blood flow and relieve PAD symptoms.
Evidence status
Ongoing clinical investigation; registries and earlier studies exist for laser atherectomy, but results for the Thor system in this study population are not yet established.
Supported by robust guideline and clinical trial evidence as standard endovascular therapy for symptomatic femoropopliteal disease, including calcified lesions; outcomes vary by lesion complexity, vessel characteristics, and adjunctive device use.
Important limitations
New device with limited published evidence; real-world performance, durability, and complication rates for Thor system are unknown. Final procedural outcomes and long-term patency await trial completion.
Balloon angioplasty and conventional atherectomy may be less effective in certain heavily calcified lesions, with risk of vessel dissection, incomplete plaque removal, residual stenosis, and restenosis. Complexity of lesion increases cost and risk.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Patient age is 6518 years
Patient agrees to participate and comply by signing consent
Patient can walk unassisted or with non-motorized aids
Patient has peripheral artery disease with Rutherford Class 2-4 in the target leg
Life expectancy greater than 12 months as judged by the investigator
Patient has new atherosclerotic disease in the native superficial femoral or popliteal arteries
Target lesion has 70% or more diameter narrowing
Lesion length is 150 mm or less
Total occlusion lesion length is less than 100 mm
Minimum vessel diameter is 4.0 mm
Guidewire has crossed the target lesion inside the artery
At least one patent tibial vessel with blood flow to the foot
Target lesion shows moderate to severe calcification by PARC criteria
You will not qualify if you...
Active infection needing antibiotics
Stenting planned in the target lesion
Positive and symptomatic COVID-19 in last 2 weeks
Pregnant or breastfeeding
Acute limb ischemia in target leg within 7 days
Stroke within 60 days
Heart attack within 60 days
Unstable coronary artery disease or other serious illness needing hospitalization in last 60 days
Allergy to aspirin or required blood-thinning medicines
Allergy to contrast dye not manageable by premedication
History of thrombophilia or heparin-induced thrombocytopenia
High serum creatinine above 2.5 mg/dL unless on dialysis
Planned major leg amputation above ankle
Recent or planned leg surgery or endovascular procedure near target lesion
Participation in another clinical trial that may interfere
Need for specialty balloons or additional atherectomy devices beyond Thor system
Significant untreated blockages before target area
Need for treatment of another lesion in the same leg distal to target at time of procedure
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit including medical history, physical exam, blood flow tests, blood and pregnancy tests, and questionnaires
Treatment
Duration - Procedure day plus up to 24 hours monitoring
Participants receive treatment with the Thor laser atherectomy system to remove calcified lesions in leg arteries. Additional devices like balloons, stents, or filters may be used as needed during the procedure.
1 procedure visit with monitoring until discharge or 24 hours after
Follow-up
Duration - 12 months
Participants return for visits at 30 days, 6 months, and 12 months after treatment for physical exams, blood flow tests, ultrasound imaging, questionnaires on walking ability and quality of life, and safety checks.
Visits at 30 days, 6 months, and 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study Evaluating Safety and Effectiveness of Acotec Drug-coated Balloon for Treating Blockages in Below-the-Knee Arteries
Post Market Follow-up Study of Acotec Drug-Coated Balloon Catheters for Lower Limb Artery Treatment in Patients with Peripheral Artery Disease
Study of Patients Treated for Aorta and Peripheral Artery Disease at Asan Medical Center
Observing Long-Term Outcomes After Revascularization Procedures
Study of Beetroot Juice to Improve Walking Ability in People with Peripheral Artery Disease PAD
Campania Registry to Collect Data and Outcomes in Patients with Peripheral Artery Disease
Community-based Structured Exercise Therapy After Revascularization to Improve Function and Cardiovascular Health in Peripheral Artery Disease
Optimal Treatment Strategies for Atherosclerotic Cardiovascular Disease Comparing Clopidogrel-Based Therapy Versus Aspirin Plus Low-Dose Rivaroxaban
Study of Shockwave Intravascular Lithotripsy to Improve Vessel Flexibility
in Patients with Severe Calcified Peripheral Arterial Disease of the Legs
Study of Drug-Coated Balloon Angioplasty for Treating Infrapopliteal Artery Lesions in Patients with Critical Limb Threatening Ischemia
Testing Far Red Light Therapy with Home-Based Walking Exercise to Improve Walking in People Aged 50 and Older with Peripheral Artery Disease
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: results of the CALCIUM 360 randomized pilot trial.
Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca⁺⁺ trial.
Clinical Safety and Efficacy of Rotational Atherectomy in Japanese Patients with Peripheral Arterial Disease Presenting Femoropopliteal Lesions: The J-SUPREME and J-SUPREME II Trials.
Shockwave™ Lithoplasty in Combination With Atherectomy in Treating Severe Calcified Femoropopliteal and Iliac Artery Disease: A Single-Center Experience.
Qais Radaideh, Nicolas W Shammas, W John Shammas...